Nicotine therapeutic benefits: Difference between revisions
Richardpruen (talk | contribs) Added stroke heading and animal study on the protective effect of nic |
Richardpruen (talk | contribs) →ADD / ADHD / Attention / Cognition: add nicotine improves memory study |
||
(One intermediate revision by one other user not shown) | |||
Line 31: | Line 31: | ||
='''ADD / ADHD / Attention / Cognition'''= | ='''ADD / ADHD / Attention / Cognition'''= | ||
=== 2025 '''[https://academic.oup.com/ntr/advance-article-abstract/doi/10.1093/ntr/ntaf060/8078909 Nicotine improves working memory via augmenting BDNF levels through α7 nAChR: evidence from clinical and pre-clinical studies]''' === | |||
* While smoking has been associated with many negative consequences to human health, one possible benefit is that nicotine could improve cognitive functions. Previous studies have suggested that smoking may influence brain-derived neurotrophic factor (BDNF) levels. | |||
* Our research revealed that tobacco product use led to an increase in working memory and human plasma BDNF levels. Furthermore, nicotine was responsible for the elevation in BDNF levels, which showed dose-dependent increases in both serum and the hippocampus, and improved memory performance. | |||
* Animal study (rat) | |||
* ''Yingyan Li, PhD, Xin Li, Yaning Fu, PhD, Wenjun Mou, Zuxin Chen, PhD, Ping Wu, PhD, Fanglin Liu, PhD, Huan Chen, PhD, Hongwei Hou, PhD, Qingyuan Hu, PhD: Nicotine & Tobacco Research'', ntaf060, <nowiki>https://doi.org/10.1093/ntr/ntaf060</nowiki> | |||
===2022 [https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2022.845646/full Tobacco and ADHD: A Role of MAO-Inhibition in Nicotine Dependence and Alleviation of ADHD Symptoms]=== | ===2022 [https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2022.845646/full Tobacco and ADHD: A Role of MAO-Inhibition in Nicotine Dependence and Alleviation of ADHD Symptoms]=== | ||
Line 539: | Line 546: | ||
='''COVID / Long COVID / Post-COVID Syndrome / Long-Haul COVID (SARS-CoV-2)'''= | ='''COVID / Long COVID / Post-COVID Syndrome / Long-Haul COVID (SARS-CoV-2)'''= | ||
*See Also: The Inflamation Section | *See Also: The Inflamation Section | ||
===2025: [https://bioelecmed.biomedcentral.com/articles/10.1186/s42234-025-00167-8 Long COVID – a critical disruption of cholinergic neurotransmission?]=== | |||
*Conclusions: "A review of the literature indicates that a significant disruption of cholinergic neurotransmission might be a central issue for both LC/ME/CFS and PVS. The hypothesis of a viral blockade of nAChRs and the possibility of a competitive reversal of this blockade by LDTN has been corroborated by highly promising results in the broad application of this method to numerous patients. Randomized controlled trials are necessary to determine whether these preliminary results can be substantiated by evidence. However, LDTN application provides many patients with a method that offers a high probability of symptom relief with only minor side effects and represents an affordable therapeutic intervention for the majority of people affected worldwide. Furthermore, dose-finding studies are required to develop individually adapted therapy regimens with regard to dosage and duration of therapy." | |||
*Citation: Leitzke, M., Roach, D.T., Hesse, S. et al. Long COVID – a critical disruption of cholinergic neurotransmission?. Bioelectron Med 11, 5 (2025). https://doi.org/10.1186/s42234-025-00167-8 | |||
=== 2023: [https://pubmed.ncbi.nlm.nih.gov/37264452/ The controversial effect of smoking and nicotine in SARS-CoV-2 infection.] === | === 2023: [https://pubmed.ncbi.nlm.nih.gov/37264452/ The controversial effect of smoking and nicotine in SARS-CoV-2 infection.] === |